TD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TD is not a clean buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has positive fundamentals and a better earnings/dividend story after Q2, but the current setup is technically stretched and the latest analyst mix is still split. Since the user is impatient and does not want to wait for the optimal entry, I would still not call this a buy today; the better call is hold and wait for a lower-risk entry.
TD is in a short-term uptrend, supported by bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive, expanding MACD histogram (0.248). However, RSI_6 at 80.683 shows the stock is overbought, which means the current price around 113.32 is extended rather than offering an attractive fresh entry. Price is also trading near resistance (R1 112.764 and R2 114.364), so upside from here looks limited near term despite the bullish trend.
Analyst firms have also been lifting targets after the report, and Jefferies and Raymond James highlighted improving breadth, better-than-expected capital markets results, and confidence in management execution.
Despite the earnings beat, there are still concerns about growth quality because one news item noted a significant decline in earnings and revenue versus last year. Barclays remains Underweight even after raising its target, which shows not all analysts are convinced. The stock is also technically overbought and has a history-based next-day and next-week downside tilt in the provided pattern analysis.
Latest quarter: fiscal Q2 2026. TD delivered adjusted EPS of C$2.38, above estimates, and revenue of C$16.04B, up 5.9% year over year. Credit provisions of C$1.00B came in below expectations, which is a positive sign for asset quality. The dividend increase reinforces management confidence, but the mixed reporting on headline earnings/revenue suggests the growth picture is improving rather than uniformly strong.
Analyst sentiment has improved recently: Barclays raised its target to C$140 but kept Underweight, Jefferies raised to C$151 and stayed Hold, BofA raised to C$168 with Buy, Raymond James upgraded to Outperform with a C$152.50 target, and Scotiabank also upgraded to Outperform with a C$150 target. The overall Wall Street view is constructive but mixed: the pros see better execution, stronger Q2 results, and improving Canadian/U.S. banking momentum; the cons still include valuation caution, residual credit/growth concerns, and at least one major firm still bearish. No recent politician or influential figure trading data is available, and there is no recent congress trading activity.
